Journal September 25, 2026 6 min read

How does hepatic steatosis work?

Hepatic steatosis, also called fatty liver disease, is the accumulation of excess lipid in hepatocytes. This page outlines the molecular pathways and research models used to study it, including FGF21–PPARα, SLC31A1–coppe

peptides-pro Editorial

Hepatic steatosis, also known as fatty liver disease, is the abnormal accumulation of lipids within hepatocytes. It is the defining histological feature of metabolic dysfunction-associated steatotic liver disease (MASLD), a condition strongly associated with obesity, insulin resistance, and type 2 diabetes [2][5]. The term encompasses a spectrum from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH), which includes inflammation and hepatocellular injury [12]. No single molecular formula or sequence defines the condition; rather, it is a multifactorial metabolic phenotype. Identifiers used in research include elevated hepatic triglyceride content, increased liver fat content (LFC) measured by MRI, and a controlled attenuation parameter (CAP) ≥248 dB/m on transient elastography [1][7].

The work centres on several intersecting pathways: the FGF21–PPARα axis regulating arachidonic acid metabolism [2], the SLC31A1-dependent copper transport pathway influencing AMPKα1 activity [5], the PNPLA3 I148M genetic variant [7], and the GLP-1/GCG receptor dual agonism targeted by mazdutide [3][6].

Research Studies

FGF21 and COX-2-mediated arachidonic acid metabolism in MASLD

In steatotic livers, both fibroblast growth factor 21 (FGF21) and cyclooxygenase-2 (COX-2) were elevated. FGF21 deficiency in mice fed a high-fat diet further augmented hepatic COX-2 expression, leading to dysregulated arachidonic acid metabolism, excessive prostaglandin E2 (PGE2) production, aggravated inflammation, and oxidative stress. These findings identify FGF21 as a suppressor of hepatic COX-2, acting through a PPARα-dependent mechanism [2]. This evidence is from animal models and in vitro work.

SLC31A1-dependent copper accumulation and AMPKα1 inactivation in T2D mice and hepatocytes

Hepatic SLC31A1 expression and copper accumulation were enhanced in HFD/STZ-induced type 2 diabetic mice and in glucosamine- or oleic acid-treated hepatocytes. This copper overload contributed to hepatic glucose and lipid metabolic disturbances through inactivation of AMPKα1 [5]. The study used both animal and cell-culture models.

PNPLA3 I148M and liver fat changes with tirzepatide in SURPASS-3 MRI

In a post hoc analysis of the SURPASS-3 MRI substudy, tirzepatide significantly reduced liver fat content versus insulin degludec in insulin-naïve patients with type 2 diabetes and MASLD. The presence of the PNPLA3 I148M allele (genotypes GG and CG) did not appear to blunt this reduction; participants with and without the allele experienced significant reductions after 52-week treatment [7]. This was a clinical study in humans.

Metformin-dapagliflozin and IGF-1 in male T2DM with MASLD

A 3-month randomized controlled trial is investigating the effects of metformin combined with dapagliflozin on serum IGF-1 levels in male patients with type 2 diabetes and MASLD. Eighty-four eligible male patients (aged 30–60 years, HbA1c 7.0%–10.0%, CAP ≥248 dB/m, on stable metformin monotherapy for ≥8 weeks) will be randomized 1:1 to continue metformin alone or receive metformin plus dapagliflozin 10 mg/day for 12 weeks. The primary endpoint is the change in serum IGF-1 from baseline to 3 months [1]. This is an ongoing clinical trial; results are not yet available.

Mazdutide in T2DM with moderate-to-severe NAFLD previously treated with semaglutide

A multicenter, prospective, randomized controlled investigator-initiated trial is evaluating the efficacy and safety of switching to mazdutide therapy in patients with type 2 diabetes and moderate-to-severe non-alcoholic fatty liver disease (NAFLD) who have achieved glycemic control. The study focuses on Chinese patients with T2DM, a population susceptible to visceral fat accumulation and increased cardiometabolic risk [3]. This is an ongoing clinical trial.

Pre-hepatectomy rehabilitation with mazdutide in obese MASLD-complicated living liver donors

The PRIME study is evaluating a 12-week prehabilitation strategy combining mazdutide (a GLP-1/GCG receptor dual agonist) with lifestyle optimization versus lifestyle optimization alone in potential living liver transplantation donors with MASLD. Overweight or obese individuals temporarily disqualified due to hepatic steatosis will be randomized 1:1 to mazdutide subcutaneous injection once weekly plus standardized lifestyle optimization or lifestyle optimization alone [6]. This is an ongoing clinical trial.

Butyrate or intensive lifestyle modification in type 1 diabetes and MASLD

A clinical trial aims to evaluate the efficacy of intensive lifestyle modification, butyrate supplementation, or their combination on hepatic steatosis in individuals with type 1 diabetes and MASLD. Butyrate, a microbiota-derived short-chain fatty acid, has emerged as a potential therapeutic approach because of its anti-inflammatory and metabolic effects [4]. This is an ongoing clinical trial.

CoQ10 effects on liver fat in mitochondrial diabetes mellitus

A prospective study is evaluating the effect of 12-week CoQ10 supplementation (300 mg/day) on liver fat content (assessed by FibroTouch CAP) in patients with mitochondrial diabetes mellitus (MDM) carrying the m.3243A>G mutation. An exploratory case-control design will compare baseline characteristics among MDM patients, type 1 diabetes patients, and healthy controls [8]. This is an ongoing clinical study.

Comparison of research models and interventions in hepatic steatosis

Intervention or target	Model / population	Key mechanism or endpoint	Evidence type
FGF21–PPARα axis	High-fat diet mice; in vitro	Suppression of COX-2, reduced PGE2, improved arachidonic acid metabolism [2]	Animal and in vitro
SLC31A1 copper transporter	HFD/STZ T2D mice; GlcN- or oleic acid-treated hepatocytes	Copper accumulation, AMPKα1 inactivation, glucose and lipid disturbances [5]	Animal and in vitro
Tirzepatide	Insulin-naïve T2D patients with MASLD (SURPASS-3 MRI)	Reduced liver fat content; effect not modified by PNPLA3 I148M [7]	Human clinical (post hoc)
Metformin + dapagliflozin	Male T2DM with MASLD	Change in serum IGF-1 at 3 months [1]	Ongoing clinical trial
Mazdutide (GLP-1/GCG dual agonist)	T2DM with moderate-to-severe NAFLD; living liver donors with MASLD	Efficacy and safety; prehabilitation for steatosis reduction [3][6]	Ongoing clinical trials
Butyrate / lifestyle modification	Type 1 diabetes with MASLD	Hepatic steatosis reduction [4]	Ongoing clinical trial
CoQ10	Mitochondrial diabetes mellitus (m.3243A>G)	Liver fat content by FibroTouch CAP [8]	Ongoing clinical study

If you are reading this for personal health reasons

The materials and compounds discussed here are sold for laboratory research only. We do not provide dosing, medical guidance, or treatment advice. Anyone considering a compound for themselves should speak to a licensed clinician.